Despite major improvements in the prevention and treatment of HIV, the prevalence of individuals living with and becoming infected by the disease remains unacceptably high. One proposed prevention strategy currently being explored is the use of pre-exposure prophylaxis (PrEP).
The idea underlying PrEP is straightforward – individuals would use existing HIV drug treatments as a prophylaxis against HIV infection. However, in addition to understanding the efficacy of these drug therapies, it is also necessary to begin an examination of how the results of the PrEP trials can be integrated into a comprehensive, global HIV prevention strategy. Researchers have noted that “public-health decisionmakers need to start contingency planning now” to prepare for the impending results of the PrEP clinical trials.
To that end, the O’Neill Institute sponsored a Bill & Melinda Gates Foundation-funded Planning for PrEP Conference in London, United Kingdom in June 2009. The conference served as a launching point to organize critical thought on the impending results of the ongoing PrEP trials. Participants included experts in the field of HIV/AIDS research, key policymakers, and representatives from NGOs.
June 18-19, 2009: “Planning for PrEP” conference, sponsored by the Bill & Melinda Gates Foundation held in London, United Kingdom with approximately thirty stakeholders working on issues relevant to PrEP throughout the world.